论文部分内容阅读
用药物降低肝硬化门静脉高压是目前研究的热点。普萘洛尔用于治疗门静脉高压的报道较多,但其不良反应限制了临床应用,联合用药是目前研究的一种趋势。近年研究发现血管紧张素Ⅱ(AngⅡ)1型受体拈抗剂有降低门静脉压力、抗肝纤维化及保护肝脏功能的作用,本实验观察了缬沙坦和普萘洛尔以及两者联合用药降低门静脉压力的疗效和对门静脉高压性胃病胃黏膜微循环及其超微结构的影响。
Using drugs to reduce portal hypertension is the current focus of research. Propranolol is widely used in the treatment of portal hypertension, but its adverse reactions limit the clinical application. Combination therapy is a trend of the current research. In recent years, studies have found that angiotensin Ⅱ type 1 receptor antagonist has the effect of reducing portal vein pressure, anti-liver fibrosis and protecting liver function. In this experiment, valsartan and propranolol and the combination of both Reduce the efficacy of portal vein pressure and gastric mucosal microcirculation and ultrastructure of portal hypertensive gastropathy.